• AERO2.40-0.06 -2.44%
  • AGTK0.010577-0.000823 -7.219302%
  • AMMJ0.565-0.075 -11.719%
  • ATTBF0.1565+0.0007 +0.4493%
  • CANN1.199-0.001 -0.083%
  • CARA12.43+0.00 +0.00%
  • CBDS2.75-0.08 -2.83%
  • CGRW0.91+0.04 +5.12%
  • CNAB0.70+0.01 +1.45%
  • DIDG0.0001+0.0000 +0.0000%
  • EDXC0.0505-0.0011 -2.2265%
  • FULL2.67+0.00 +0.00%
  • GBLX0.25745+0.03245 +14.42223%
  • GRNH0.03628+0.00328 +9.93939%
  • GWPH105.08-2.55 -2.37%
  • HEMP0.019-0.001 -3.308%
  • INCC0.00035-0.00005 -12.50000%
  • INSY7.53-0.08 -1.05%
  • LXRP0.41+0.02 +5.13%
  • MCIG0.1645-0.0048 -2.8352%
  • MJNA0.0697+0.0007 +1.0145%
  • MJNE0.942-0.041 -4.171%
  • MNTR0.697481-0.113519 -13.997412%
  • NDEV0.277-0.013 -4.450%
  • NTRR0.0799-0.0011 -1.3580%
  • OXIS0.063-0.029 -31.522%
  • PMCB0.0554-0.0013 -2.2065%
  • PLPL0.009+0.000 +0.000%
  • RSSFF0.054-0.003 -5.462%
  • SPRWF1.11+0.00 +0.00%
  • SRNA0.114059+0.006559 +6.101395%
  • STEV0.0012+0.0000 +0.0000%
  • TRTC0.19-0.00 -0.68%
  • TURV0.38-0.08 -17.39%
  • TWMJF10.2355+0.1065 +1.0514%
  • XXII2.78+0.12 +4.51%
  • ZDPY0.82+0.02 +2.50%
  • AUDUSD=X0.7821
  • USDJPY=X113.3070
To show stock chart
Aurora-night-sky-600×300

Aurora Applauds Federal Task Force Report on Cannabis Legalization

TSXV: ACB

VANCOUVERDec. 13, 2016 /CNW/ – Aurora Cannabis Inc. (the “Company” or “Aurora”) (TSXV: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) today responded to the recommendations of the Task Force on Cannabis Legalization as presented today.

“We welcome the recommendations from the Task Force members, who have taken a thorough, balanced and well informed approach to compiling this report,” said Terry Booth, CEO.  “While we need to digest the full findings of the report, we are very pleased by many of the Task Force’s recommendations, including maintaining a separate medical access framework for patients. We also support the report’s comment with regard to the need for federally supported research into the use of cannabis and cannabinoids for medical purposes, with the explicit aim of facilitating their market authorization as drugs. This will help address affordability and insurance coverage issues. It is encouraging to hear the Task Force suggest there should be a diversified market that builds upon the existing quality control and consumer protection offered by existing federally-licensed producers, which will ensure Canadians benefit from continued innovation and competitiveness, while allowing the pioneers in this space to have the opportunity to participate. We were also pleased to see the comments pertaining to federally regulated production of cannabis and its derivatives, including edibles and concentrates.  This constitutes a considerable market opportunity that we look forward to elevating to the Aurora Standard.”

The Task Force, which included experts from academia, medicine, law-enforcement, and industry, conducted an extensive public consultation over the course of many months, receiving nearly 30,000 responses and submissions from nearly 300 organizations.

Cam Battley, Executive Vice President at Aurora said, “For several years now, Canada’s Licensed Producers have established a well-regulated Canadian system for the production and distribution of medical cannabis that is now a model to the world. The Task Force has recognized that expanding the proven, successful system that exists for medical cannabis to include non-medical users, with the addition of broader product categories, is an effective and efficient way for the Government of Canada to deliver on its promise to legalize marijuana while meeting its public health and public safety objectives. We hope that the Government will quickly endorse the Task Force’s recommendations. While Aurora looks forward to participating in the broader consumer market, we remain committed to providing our current clients with high-quality, affordable and quality controlled medical cannabis.”

About Aurora

Aurora’s wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR) and operates a 55,200 square foot, expandable, state-of-the-art production facility in Mountain View County, Alberta, Canada. Aurora trades on the TSX Venture Exchange under the symbol “ACB”.

On behalf of the Board of Directors,
AURORA CANNABIS INC.

Terry Booth
CEO

This news release contains certain “forward-looking statements” within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law. 

The TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. 

SOURCE Aurora Cannabis Inc. 

For further information: Cam Battley, Executive Vice President, +1.905.864.5525, cam@auroramj.com, www.auroramj.com; Marc Lakmaaker, NATIONAL Equicom, mlakmaaker@national.ca, +1.416.848.1397



CANNABIS ENTREPRENEURS
READ BLUNT

SIGN UP FOR FREE WEEKLY CANNABIS
BUSINESS NEWS, ANALYSIS AND ALERTS